Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
Not Confirmed
Not Confirmed
07-09 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Industry Trade Show
Not Confirmed
07-09 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/bms-j-j-bayer-lead-25-000-pharma-layoffs-in-2024-amylyx-fibrogen-kronos-bio-hit-by-trial-failures-cash-crunch
18 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/18/2999072/0/en/Akari-Therapeutics-Announces-Key-Leadership-Appointments.html
16 Dec 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/12/16/2997598/0/en/Akari-Therapeutics-Appoints-Torsten-Hombeck-Ph-D-as-Chief-Financial-Officer.html
19 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/19/2983556/0/en/Akari-Therapeutics-Regains-Full-Nasdaq-Compliance.html
14 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/14/2981638/0/en/Akari-Therapeutics-Announces-Successful-Completion-of-Merger-of-Akari-Therapeutics-and-Peak-Bio.html
08 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/08/2977608/0/en/Akari-Therapeutics-Announces-Shareholder-Approval-in-Connection-With-Peak-Bio-Inc-Merger.html
15 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/15/2963146/0/en/Akari-Therapeutics-Announces-Effectiveness-of-Form-S-4-and-General-Meeting-Date-of-November-7-2024-Related-to-Peak-Bio-Merger.html
Details:
The combined company will have an expanded pipeline containing multiple assets in early and late development stages, including a novel pre-clinical ADC candidate targeting TROP-2 for cancer patients.
Lead Product(s): ADC-based Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Recipient: Peak Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 14, 2024
Lead Product(s) : ADC-based Therapy
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Peak Bio
Deal Size : Undisclosed
Deal Type : Merger
Akari Completes Merger with Peak Bio Successfully
Details : The combined company will have an expanded pipeline containing multiple assets in early and late development stages, including a novel pre-clinical ADC candidate targeting TROP-2 for cancer patients.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 14, 2024
Details:
PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 (LTB4) product candidate for intravitreal treatment of geographic atrophy (GA).
Lead Product(s): PAS-Nomacopan
Therapeutic Area: Ophthalmology Brand Name: rVA576
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2024
Lead Product(s) : PAS-Nomacopan
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akari Therapeutics Gets FDA Pre-IND Feedback on PAS-nomacopan For Geographic Atrophy
Details : PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 (LTB4) product candidate for intravitreal treatment of geographic atrophy (GA).
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 19, 2024
Details:
The combined company will have an expanded pipeline that contains multiple compelling assets (early and late development), including a novel pre-clinical ADC candidate targeting TROP-2 for cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Large molecule
Recipient: Peak Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Peak Bio
Deal Size : Undisclosed
Deal Type : Merger
Akari and Peak Bio Announce Merger Creating Expanded Pipeline with Novel ADC Toolkit
Details : The combined company will have an expanded pipeline that contains multiple compelling assets (early and late development), including a novel pre-clinical ADC candidate targeting TROP-2 for cancer.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 05, 2024
Details:
rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Lead Product(s): Nomacopan
Therapeutic Area: Ophthalmology Brand Name: rVA576
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 27, 2023
Details:
rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Lead Product(s): Nomacopan
Therapeutic Area: Hematology Brand Name: rVA576
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 13, 2023
Details:
rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in pre-clinical for Geographic Atrophy.
Lead Product(s): Nomacopan
Therapeutic Area: Ophthalmology Brand Name: rVA576
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in pre-clinical for Geographic Atrophy.
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 11, 2023
Details:
rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Lead Product(s): Nomacopan
Therapeutic Area: Hematology Brand Name: rVA576
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 06, 2023
Details:
rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Lead Product(s): Nomacopan
Therapeutic Area: Hematology Brand Name: rVA576
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : rVA576 (nomacopan) is an investigational bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4) currently in Phase 3 clinical trials for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 03, 2023
Details:
The net proceeds are expected to support advancement of Akari’s two priority pipeline programs investigating rVA576 (nomacopan), a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4).
Lead Product(s): Nomacopan
Therapeutic Area: Hematology Brand Name: rVA576
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Paulson Investment Company
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 30, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Paulson Investment Company
Deal Size : $4.0 million
Deal Type : Public Offering
Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering
Details : The net proceeds are expected to support advancement of Akari’s two priority pipeline programs investigating rVA576 (nomacopan), a bispecific recombinant inhibitor of complement C5 and leukotriene B4 (LTB4).
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 30, 2023
Details:
rVA576 (nomacopan) is a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) in clinical development for pediatric and adult HSCT-TMA.
Lead Product(s): Nomacopan
Therapeutic Area: Hematology Brand Name: rVA576
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Lead Product(s) : Nomacopan
Therapeutic Area : Hematology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding M...
Details : rVA576 (nomacopan) is a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4) in clinical development for pediatric and adult HSCT-TMA.
Brand Name : rVA576
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 29, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?